Extracorporeal Immune Support System (EISS) for the Treatment of Septic

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02391792` - Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance	N/A
Completed	`NCT02030158` - Statistical Analysis Plan for an Individual Patient Data Meta-analysis of Three, International Trials Comparing Protocolised With Usual Resuscitation in Patients Presenting to the Emergency Department With Severe Sepsis and Septic Shock
Recruiting	`NCT02300415` - Comparison of Sensitivity Between Presepsine and Lactate for the Diagnosis of Severe Sepsis.	N/A

See also

Status

Clinical Trial

Phase

Recruiting

NCT02391792 - Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance

N/A

Completed

NCT02030158 - Statistical Analysis Plan for an Individual Patient Data Meta-analysis of Three, International Trials Comparing Protocolised With Usual Resuscitation in Patients Presenting to the Emergency Department With Severe Sepsis and Septic Shock

Recruiting

NCT02300415 - Comparison of Sensitivity Between Presepsine and Lactate for the Diagnosis of Severe Sepsis.

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT00818597
Study type	Interventional
Source	University of Rostock
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	December 2003
Completion date	June 2008

Extracorporeal Immune Support System (EISS) for the Treatment of Septic Patients — EISS-1

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms